Pharma Surge
Pharma Surge
Intelligence Layer

News

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

Hub signal

Search-friendly coverage

Keep the current route structure, but present it with the same premium hierarchy as the homepage.

Explore

Search-friendly hub pages

Regulators

01

Regulatory Updates

FDA, EMA, PMDA, MHRA, and global regulatory coverage in one crawlable hub.

Open hub

Trials

02

Clinical Trial Watch

Phase readouts, trial design updates, enrollment milestones, and study results.

Open hub

Pipeline

03

Drug Pipeline

Regulatory pipeline signals, approvals, and market-moving development updates.

Open hub
Live pharma index

Full coverage

Every signal, indexed and searchable

Browse the complete catalog across approvals, trials, research, devices, and deals - refreshed twice a day.

350+

trusted sources

8k+

indexed stories

2x

daily refresh

Coverage

Latest indexed stories

9,192 stories indexed, page 105 of 154

🌍Industryguerbet.com
Featured signal

Guerbet en bonne position dans le Gaïa Index 2019 pour la 2ème année consécutive

Publisher

Guerbet

Limited excerpt on-platform. Click anywhere on this card to open the original publisher in a new tab.

GuerbetOriginal publisher link

Canonical metadata stays public, while full text remains on the original site.

🇬🇧Researchhdruk.ac.uk

MyEyeSite: creating a patient-owned repository of inherited retinal disease data

Health Data Research UKOriginal source
🇩🇰Industryserviersymphogen.com

Servier underskriver endelig aftale om at erhverve Symphogen, en førende antistof discovery virksomhed, for at styrke Serviers kapacitet inden for antistoffer samt dets forskning og udvikling

SymphogenOriginal source
🇩🇰Industryserviersymphogen.com

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

SymphogenOriginal source
🇺🇸Researchcidrap.umn.edu

News Scan for Apr 02, 2020

CIDRAPOriginal source
🇺🇸Researchcidrap.umn.edu

Stewardship / Resistance Scan for Apr 02, 2020

CIDRAPOriginal source
🇧🇪Regulatoryfamhp.be

Pilot project on simultaneous national scientific advice starts 1 February 2020

FAMHP (Belgium)Original source
🇺🇸CDMOnoramco.com

Meet us at DCAT Week

NoramcoOriginal source
🌍Industryan2therapeutics.com

AN2 Therapeutics Launches with $12 Million in Series A

AN2 TherapeuticsOriginal source
🌍Industryemzorpharma.com

Emzor Wellocracy Radio Show with Pharm Tosin Oguntoye

Emzor PharmaceuticalOriginal source
🌍Industryemzorpharma.com

Emzor Wellocracy Radio Show with Pharm Funmbi Okoya

Emzor PharmaceuticalOriginal source
🌍Industryemzorpharma.com

Emzor Wellocracy Radio Show with Pharm Kehinde Adepoju

Emzor PharmaceuticalOriginal source
🌍Industryemzorpharma.com

Emzor Wellocracy Radio Show with Pharm Muyiwa Olagunju

Emzor PharmaceuticalOriginal source
🇺🇸Researchcidrap.umn.edu

Stewardship / Resistance Scan for Aug 30, 2019

CIDRAPOriginal source
🇺🇸CROflorencehc.com

Why Remote Clinical Trial Monitoring is the New Standard

Florence HealthcareOriginal source
🌍Industryir.cyclerion.com

Cyclerion Therapeutics Reports Second Quarter 2019 Financial Results and Progress on Four Clinical Studies with Data Readouts Anticipated in the Next 12 Months

Cyclerion TherapeuticsOriginal source
🇺🇸CROflorencehc.com

Overcoming Four Common Challenges in Multicenter Research

Florence HealthcareOriginal source
🌍Industrycervomed.com

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Dementia with Lewy Bodies - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma Appoints Noel Donnelly as CFO - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma Initiates New Study with Neflamapimod for the Treatment of Cognitive Deficits in Patients with Huntington's Disease - CervoMed

CervoMedOriginal source
🇺🇸CROflorencehc.com

Integrating the eTMF and eISF: Why and Why Now?

Florence HealthcareOriginal source
🌍Industrycervomed.com

EIP Pharma to Host KOL Breakfast Briefing on Potential of Neflamapimod in Alzheimer's Disease and Dementia with Lewy Bodies - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma to Present at Upcoming Investor Conferences in June - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma Closes $11.2 Million Financing Round to Advance Development of Neflamapimod in Additional Neurodegenerative Disease Indications - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma to Present at BIO CEO Investor Conference - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma Announces Phase 2B REVERSE-SD Study of Neflamapimod Fully Enrolled - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma Secures $20.5 Million in Series B Financing - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma Announces Publication of Positive Alzheimer's Disease Clinical Study Data with Neflamapimod - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma announces presentation of new mechanism of action data regarding neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC) - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma announces presentation of new positive clinical data with neflamapimod (VX-745) at Alzheimer's Association International Conference (AAIC) - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma announces scientific publication of results demonstrating pro-cognitive effects in aged rats of VX-745, a clinical stage selective p38 MAP kinase alpha Inhibitor - CervoMed

CervoMedOriginal source
🌍Industrycervomed.com

EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) - CervoMed

CervoMedOriginal source
🇺🇸CROflorencehc.com

Technology in Multicenter Clinical Trials

Florence HealthcareOriginal source
🌍Industryemzorpharma.com

AFCON 2019 Kicks Off Today!

Emzor PharmaceuticalOriginal source
🌍Industryir.cyclerion.com

Cyclerion Therapeutics to Present Preclinical Data on its Clinical-Stage sGC Stimulators for Neurodegenerative and Cardiometabolic Diseases at the 9th International Conference on cGMP

Cyclerion TherapeuticsOriginal source
🌍Industryemzorpharma.com

Dr Stella Okoli, CEO Emzor Pharmaceutical to be Inducted into Nigerian Women Hall of Fame by Federal Government

Emzor PharmaceuticalOriginal source
🌍Industryir.cyclerion.com

Cyclerion Therapeutics to Present Data on its Sickle Cell Disease Program at Upcoming Medical and Scientific Meetings

Cyclerion TherapeuticsOriginal source
🌍Industryemzorpharma.com

Emzor Para 1000 Features in Music Video, Ringi Ringi by Akuchi Ft. Olamide

Emzor PharmaceuticalOriginal source
🇩🇰Industryserviersymphogen.com

Symphogen publishes discovery and pre-clinical data on first chicken-derived antibody to enter human clinical trials

SymphogenOriginal source
🇩🇰Industryserviersymphogen.com

Symphogen announces new capital raise and explores strategic options

SymphogenOriginal source
🌍Industryir.cyclerion.com

Cyclerion Therapeutics Provides a Corporate and Pipeline Overview as a Newly Launched Public Biopharmaceutical Company

Cyclerion TherapeuticsOriginal source
🌍Industryir.cyclerion.com

Cyclerion to Host Corporate Overview Call on May 13, 2019

Cyclerion TherapeuticsOriginal source
🇺🇸CROflorencehc.com

FDA: Technology’s Value in a World of Precision Medicine and Research

Florence HealthcareOriginal source
🌍Industryir.cyclerion.com

Cyclerion Announces the Appointment of Andreas Busch, Ph.D., as Chief Innovation Officer

Cyclerion TherapeuticsOriginal source
🌍Industryir.cyclerion.com

Cyclerion Launches as Clinical-Stage Biopharmaceutical Company Harnessing the Power of Soluble Guanylate Cyclase (sGC) Pharmacology for Treatment of Serious and Orphan Diseases

Cyclerion TherapeuticsOriginal source
🇺🇸CROflorencehc.com

ALCOA-C in Clinical Trial Electronic Document Management

Florence HealthcareOriginal source
🇺🇸Researchcidrap.umn.edu

Stewardship / Resistance Scan for Mar 18, 2019

CIDRAPOriginal source
🌍Industryemzorpharma.com

Emzor’s Position on the BBC Documentary on Codeine

Emzor PharmaceuticalOriginal source
🇺🇸Researchcidrap.umn.edu

Antibiotics before miscarriage surgery not tied to fewer infections

CIDRAPOriginal source
🌍Industryir.cyclerion.com

Cyclerion, the Planned R&D Spin-off of Ironwood Pharmaceuticals, Secures Commitments of $175 Million in Private Offering

Cyclerion TherapeuticsOriginal source
🇺🇸CROflorencehc.com

5 Key Advantages of eRegulatory

Florence HealthcareOriginal source
🇺🇸CROflorencehc.com

Observations from TMF Summit 2019: The Post-eTMF World

Florence HealthcareOriginal source
🌍Industryir.cyclerion.com

Ironwood Announces Filing of Form 10 Registration Statement in Connection with Planned Business Separation

Cyclerion TherapeuticsOriginal source
🇺🇸CROflorencehc.com

How Lauren Begnaud Transitioned 65 Sites to eRegulatory at US Oncology

Florence HealthcareOriginal source
🇺🇸CROflorencehc.com

Thank you for a great 2018!

Florence HealthcareOriginal source
🇺🇸CROflorencehc.com

Key Expectations of Clinical Trial Operations Leaders in 2019

Florence HealthcareOriginal source
🇺🇸CROflorencehc.com

Four Observations from Site Solutions Summit

Florence HealthcareOriginal source